Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Tapan M. Kadia"'
Autor:
Koichi Takahashi, Nitin Jain, Guillermo Garcia-Manero, Lucia Masarova, Sa Wang, Courtney D. DiNardo, Naveen Pemmaraju, Guillermo Montalban Bravo, Tapan M. Kadia, Sanam Loghavi, Musa Yilmaz, Ghayas C. Issa, Koji Sasaki, Elias Jabbour, Steven M. Kornblau, Abhishek Maiti, Marina Konopleva, Lianchun Xiao, Curtis Lachowiez, Maria Adeoti, Farhad Ravandi, Michael Andreeff, Nicholas J. Short, Gautam Borthakur, Hagop M. Kantarjian, Naval Daver, Yesid Alvarado
Publikováno v:
J Clin Oncol
PURPOSE Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients relapse. Relapsed or refractory AML (R/R-AML) remains a particularly adverse p
Autor:
Jayastu Senapati, Elias Jabbour, Nicholas James Short, Farhad Ravandi, Partow Kebriaei, Tapan M. Kadia, Gautam Borthakur, Naveen Pemmaraju, Rebecca Garris, Divyam Bansal, Sergej Konoplev, Sa A Wang, Wei Wang, Guilin Tang, Keyur P. Patel, Marina Konopleva, Nitin Jain
Publikováno v:
Journal of Clinical Oncology. 40:7040-7040
7040 Background: CRLF2 rearranged B-ALL, a subtype of Ph-like ALL, constitutes a high-risk subset of B-ALL with poor outcomes with chemotherapy. Targeted therapies such as blinatumomab (blina) or inotuzumab (ino) may improve treatment outcomes for th
Autor:
Faustine Ong, Farhad Ravandi, Uday R. Popat, Tapan M. Kadia, Naval Guastad Daver, Courtney Denton Dinardo, Marina Konopleva, Gautam Borthakur, Elizabeth J. Shpall, Betul Oran, Gheath Alatrash, Rohtesh S. Mehta, Elias Jabbour, Musa Yilmaz, Ghayas C. Issa, Guillermo Garcia-Manero, Abhishek Maiti, Hussein Abbas, Richard E. Champlin, Nicholas James Short
Publikováno v:
Journal of Clinical Oncology. 40:7038-7038
7038 Background: The optimal induction regimen for older patients (pts) with AML who are eligible for SCT is not well-established. Methods: This is a retrospective analysis of 127 pts age ≥60 years with newly diagnosed AML who underwent allogeneic
Autor:
Daniel Nguyen, Jing Ning, Wei Qiao, Koji Sasaki, Hagop M. Kantarjian, Nicholas James Short, Branko Cuglievan, Naval Guastad Daver, Courtney Denton Dinardo, Elias Jabbour, Tapan M. Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Farhad Ravandi, Ghayas C. Issa
Publikováno v:
Journal of Clinical Oncology. 40:7026-7026
7026 Background: Acute myeloid leukemia (AML) with rearrangement of KMT2A is characterized by chemotherapy resistance and high rates of relapse. However, additional causes of treatment failure or early mortality have not been well-defined in this ent
Autor:
Naszrin Arani, Nadya Jammal, Alexis Geppner, Kunhwa Kim, Gautam Borthakur, Nitin Jain, Marina Konopleva, Guillermo Garcia-Manero, Alessandra Ferrajoli, Elias Jabbour, Hagop M. Kantarjian, Tapan M. Kadia
Publikováno v:
Journal of Clinical Oncology. 40:e19087-e19087
e19087 Background: T-cell prolymphocytic leukemia (T-PLL) is an ultra-rare and aggressive mature T-cell leukemia associated with a poor prognosis. First-line therapy is with CD52 monoclonal antibody alemtuzumab and allogenic stem cell transplant (SCT
Autor:
Musa Yilmaz, Muharrem Muftuoglu, Hagop M. Kantarjian, Courtney Denton Dinardo, Tapan M. Kadia, Marina Konopleva, Gautam Borthakur, Naveen Pemmaraju, Nicholas James Short, Yesid Alvarado Valero, Abhishek Maiti, Lucia Masarova, Guillermo Montalban Bravo, Sanam Loghavi, Steven Mitchell Kornblau, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Michael Andreeff, Naval Guastad Daver
Publikováno v:
Journal of Clinical Oncology. 40:7036-7036
7036 Background: QUIZ, a potent 2nd generation FLT3 inhibitor (FLT3i) demonstrated synergy with VEN in AML cell lines and PDX models (Mali Haematologica 2020). We evaluated the safety and efficacy of DAC + VEN + QUIZ triplet in patients with newly di
Autor:
Farhad Ravandi, Tareq Abuasab, Yesid Alvarado Valero, Ghayas C. Issa, Rabiul Islam, Nicholas James Short, Musa Yilmaz, Nitin Jain, Lucia Masarova, Steven Mitchell Kornblau, Elias Jabbour, Naveen Pemmaraju, Guillermo Montalban Bravo, Sherry Pierce, Courtney Denton Dinardo, Tapan M. Kadia, Naval Guastad Daver, Marina Konopleva, Guillermo Garcia-Manero
Publikováno v:
Journal of Clinical Oncology. 40:7037-7037
7037 Background: ASTX727, is an oral formulation of the fixed dose combination of decitabine and cytidine deaminase inhibitor cedazuridine (100 mg/35 mg). We investigated whether a total oral therapy regimen of ASTX727+ven is feasible and safe. Metho
Autor:
Curtis Andrew Lachowiez, Jacqueline Suen Garcia, Gautam Borthakur, Sanam Loghavi, Zhihong Zeng, George Dono Tippett, Tapan M. Kadia, Lucia Masarova, Musa Yilmaz, Abhishek Maiti, Prithviraj Bose, Koichi Takahashi, Elias Jabbour, Farhad Ravandi, Naval Guastad Daver, Guillermo Garcia-Manero, Paresh Vyas, Hagop M. Kantarjian, Marina Konopleva, Courtney Denton Dinardo
Publikováno v:
Journal of Clinical Oncology. 40:7018-7018
7018 Background: Isocitrate dehydrogenase-1 mutations ( IDH1+) result in production of the oncometabolite 2-hydroxyglutarate, arrested differentiation, and increased dependence on the anti-apoptotic protein BCL-2, enhancing susceptibility to the BCL-
Autor:
Nicholas James Short, Hagop M. Kantarjian, Marina Konopleva, Guillermo Montalban Bravo, Farhad Ravandi, Nitin Jain, Tapan M. Kadia, Yesid Alvarado Valero, Kelly Sharon Chien, Naval Guastad Daver, Walid Macaron, Koji Sasaki, Jennifer Thankachan, Ricardo Delumpa, Ejiroghene Mayor, Wuliamatu Deen, Christopher Loiselle, Monica Kwari, Rebecca Garris, Elias Jabbour
Publikováno v:
Journal of Clinical Oncology. 40:7009-7009
7009 Background: Ponatinib and blinatumomab are highly active in Ph+ ALL. A chemotherapy-free combination of these agents may lead to durable remissions and reduce the need for stem cell transplant (SCT) in first remission. Methods: In this phase II
Autor:
Sai Prasad Desikan, Guillermo Montalban-Bravo, Maro Ohanian, Naval Guastad Daver, Tapan M. Kadia, Sangeetha Venugopal, Kelly Sharon Chien, Rashmi Kanagal-Shamanna, Hagop M. Kantarjian, Guillermo Garcia-Manero
Publikováno v:
Journal of Clinical Oncology. 40:e19068-e19068
e19068 Background: The prognosis of patients with higher-risk (HR) MDS after hypomethylating agent (HMA) failure is poor with a survival of 4-6 months (Garcia-Manero et al, Lancet Oncology 2016). The combination of azacitidine (Aza) with venetoclax (